TAXOL INFUSION

Ovarian carcinoma- For previously untreated patients: Intravenous (as a twenty-four hour infusion), 135 mg per square meter of body surface area, followed by cisplatin 75 mg per square meter of body surface area, repeated every twenty-one days. (Canadian product labeling recommends a dose of 175 mg per square meter of body surface area, followed by cisplatin 75 mg per square meter of body surface area, as a three-hour intravenous infusion, repeated every twenty-one days). For previously treated patients: Intravenous (as a three or twenty-four-hour infusion), 135 or 175 mg per square meter of body surface area, repeated every twenty-one days . (Canadian product labeling recommends a dose of 175 mg per square meter of body surface area as a three - or twenty-four-hour intravenous infusion, repeated every twenty-one days.) Breast carcinoma- Intravenous (as a three-or twenty-four-hour infusion), 175 mg per square meter of body surface area, repeated every twenty-one days . Breast carcinoma, node-positive - Intravenous (as a three-hour infusion), 175 mg per square meter of body surface area, repeated every twenty-one days for four courses administered sequentially to doxorubicin-containing combination chemotherapy. AIDS-associated Kaposi's sarcoma - Intravenous (as a three- or twenty-four-hour infusion), 135 mg per square meter of body surface area, repeated every twenty-one days or Intravenous (as a three- or twenty-four-hour infusion), 100 mg per square meter of body surface area, repeated every fourteen days . Carcinoma, lung, non-small cell - Intravenous (as a twenty-four-hour infusion), 135 mg per square meter of body surface area followed by cisplatin 75 mg per square meter of body surface area, repeated every twenty-one days (Canadian product labeling recommends a dose of 175 mg per square meter of body surface area as a three-hour intravenous infusion, followed by cisplatin, repeated every twenty-one days.) . [Carcinoma, bladder] or [Carcinoma, head and neck] or [Carcinoma, cervical] or [Carcinoma, esophageal] or [Carcinoma, endometrial] or [Carcinoma, lung, small cell] or [Carcinoma, prostate] or [Carcinoma, gastric] - Consult medical literature and manufacturer's literature for specific dosage. Note: To prevent severe hypersensitivity reactions, all patients should be premedicated with corticosteroids (e.g., dexamethasone 20 mg orally or intravenously [patients with solid tumors] or dexamethasone 10 mg orally [patients with AIDS-associated Kaposi's sarcoma] approximately twelve and six hours prior to paclitaxel administration); diphenhydramine (e.g., 50 mg intravenously, thirty to sixty minutes prior to paclitaxel) or its equivalent; and cimetidine (e.g., 300 mg intravenously, thirty to sixty minutes prior to paclitaxel), ranitidine (e.g., 50 mg intravenously, thirty to sixty minutes prior to paclitaxel) , or famotidine (e.g., 20 mg intravenously, thirty to sixty minutes prior to paclitaxel) . Contact of paclitaxel with plasticized polyvinyl chloride (PVC) equipment or devices must be avoided because of the risk of patient exposure to the plasticizer DEHP (di-[2-ethylhexyl]phthalate), which may be leached from PVC infusion bags or sets . Paclitaxel solutions should be diluted and stored in glass or polypropylene bottles or in plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets . Paclitaxel intravenous infusion should be administered through an in-line filter with a microporous membrane not greater than 0.22 microns . Use of filter devices that incorporate short inlet and outlet PVC-coated tubing has not resulted in significant leaching of DEHP . Frequent changing of filters (e.g., every twelve hours) may be necessary because of clogging during the infusion .

MAXIMUM ADULT DOSE:

PEDIATRIC DOSE:

Safety and efficacy in pediatric patients have not been established .

MAXIMUM PEDIATRIC DOSE:

ELDERLY DOSE:

PREVIOUS

NEXT